Latest receivables for CCEL: $6.9M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (May 2026), CCEL shows a receivables of $6.9M. That compares with $6.9M in the prior-year period — down 0.3% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, CCEL's receivables is now $6.9M (was $6.9M) — a 0.3% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Cryo-Cell International is outperforming or lagging.
Tracking CCEL's receivables over time shows whether Cryo-Cell International is scaling, shrinking, or reshaping that part of the business. The current reading is $6.9M That compares with $6.9M in the prior-year period — down 0.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this receivables page, Stockcircle has Cryo-Cell International's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $6.9M) with ownership activity and broader fundamentals.
Cryo-Cell International's receivables is $6.9M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.